Hydrocortisone aceponate activity and benefit/risk ratio in relation to reference topical glucocorticoids.
The evaluation of the benefit/risk ratio (BRR) for topical glucocorticoids (TGC) allows the comparison of active ingredients and thereby includes aspects of dosage (blanching response, BR) as well as adverse effects (skin atrophy). In the present study, the BRR of hydrocortisone aceponate, prednicarbate and betamethasone valerate was investigated according to an adapted procedure for investigating the BR. The main difference is the longer application period of the investigational substance without occlusion. Thus, the pharmacokinetic characteristics of all of the systems are considered more intensely and the penetration conditions are designed in a realistic way, namely oriented towards the preparation in order to improve the significance and relevance of the BRR for practical use. The results demonstrate that the investigated substances also show differences in the extent of the BR, but on the other hand they show that the improved penetration characteristics of the double-esterified compounds are clearly less effective. In comparison to the BRR, this results to a large extent in a balanced picture without relevant advantages for single preparations. Nevertheless, the already mentioned positive characteristics of the investigated TGC and the positive practical clinical experiences have been approved. Further investigations have to show whether the method presented here for investigating the BR offers advantages in the comparative assessment of TGC.
Wohlrab
J
J
Department of Dermatology and Venereology, Martin Luther University Halle-Wittenberg, Halle/Saale, Germany. johannes.wohlrab @ medizin.uni-halle.de
Beck
G M
GM
Neubert
R H H
RH
Sischka
U
U
Kreft
B
B
D000287:Administration, Topical; D000328:Adult; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000378:metabolism* / Q000627:therapeutic use; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012015:Reference Standards; D012307:Risk Factors; D012869:Skin Absorption / Q000187:drug effects* / Q000502:physiology*; D055815:Young Adult
D005938:Glucocorticoids; C063919:hydrocortisone aceponate; D006854:Hydrocortisone